Mollugin Has an Anti-Cancer Therapeutic Effect by Inhibiting TNF-α-Induced NF-κB Activation.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal xenograft research with no human data
PubMed 28933726 · doi:10.3390/ijms18081619
What was done
Researchers investigated the anticancer effects and mechanism of mollugin, derived from *Rubia cordifolia* L. roots, against TNF-α-induced NF-κB activation. In HeLa cells, they evaluated NF-κB reporter gene expression, phosphorylation of IKK, phosphorylation and degradation of IκBα, and p65 phosphorylation and nuclear translocation. Downstream expression of genes regulating proliferation (COX-2, Cyclin D1, c-Myc), anti-apoptosis (Bcl-2, cIAP-1, survivin), invasion (MMP-9, ICAM-1), and angiogenesis (VEGF) was assessed, along with cell proliferation and apoptosis assays. Antitumor efficacy was also tested in vivo using a HeLa-derived tumor xenograft model.
What was found
The abstract reports no numerical values, doses, or statistical metrics. Mollugin inhibited TNF-α-induced NF-κB reporter gene expression in a dose-dependent manner and blocked TNF-α-induced IKK phosphorylation, IκBα phosphorylation/degradation, and p65 nuclear translocation. Pretreatment reduced the expression of target genes related to proliferation, anti-apoptosis, invasion, and angiogenesis. Mollugin also potentiated TNF-α-induced apoptosis, inhibited HeLa cell proliferation, and suppressed xenograft tumor growth.
Why it matters
The study characterizes mollugin as a natural inhibitor of NF-κB signaling that suppresses oncogenic gene expression and xenograft growth in preclinical models.
Limits
The abstract provides no numerical data, concentration ranges, animal sample sizes, or variance estimates. The evidence is strictly preclinical (in vitro cell lines and animal xenografts) and cannot establish efficacy or safety in humans.
Cited by
- supports The transcription factor NF-κB regulates about 200 genes involved in immune response and regulates vascular endothelial growth factor (VEGF).